Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Vanda Investigational Site
Rogers, Arkansas, United States
Vanda Investigational Site
Costa Mesa, California, United States
Vanda Investigational Site
Lemon Grove, California, United States
Vanda Investigational Site
Oceanside, California, United States
Vanda Investigational Site
Pico Rivera, California, United States
Vanda Investigational Site
San Diego, California, United States
Vanda Investigational Site
Walnut Creek, California, United States
Vanda Investigational Site
North Miami, Florida, United States
Vanda Investigational Site
Atlanta, Georgia, United States
Vanda Investigational Site
Peachtree Corners, Georgia, United States
Start Date
May 14, 2025
Primary Completion Date
November 1, 2027
Completion Date
November 1, 2027
Last Updated
January 12, 2026
400
ESTIMATED participants
iloperidone
DRUG
placebo
DRUG
Lead Sponsor
Vanda Pharmaceuticals
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions